Amgen Inc. AMGN
Amgen Inc. is a leading global biotechnology company that discovers, develops, manufactures, and delivers innovative human therapeutics. The company focuses on serious illnesses where there is a significant unmet medical need, primarily in the areas of oncology, hematology, cardiovascular disease, inflammation, bone health, neuroscience, and nephrology. Amgen serves patients worldwide through a direct sales force and marketing partners, leveraging advanced human genetics and biotechnology to transform new ideas and discoveries into medicines. Amgen's business model is centered on research and development of biologic medicines, which are large-molecule drugs derived from living organisms. The company markets a portfolio of important medicines including Prolia/XGEVA for bone health, Enbrel for inflammatory diseases, Repatha for cardiovascular conditions, and various oncology products like KYPROLIS and BLINCYTO. Amgen generates revenue primarily through product sales of these patented biologic therapies to healthcare providers, hospitals, and pharmacies across the United States and international markets. The company operates extensive manufacturing facilities to produce its complex biologic products and maintains a robust pipeline of investigational therapies across multiple therapeutic areas. Amgen invests significantly in research and development to advance its pipeline through clinical trials, while also pursuing strategic acquisitions and partnerships to expand its portfolio and geographic reach. The company's operations are subject to extensive government regulation by agencies like the FDA and EMA, which oversee drug approval, manufacturing, and marketing.
LSTM Forecast
Forecast model is not trained yet for this market.
Train and backfill the LSTM forecast to surface a directional view here.